The vascular effects of doxazosin in hypertension complicated by metabolic syndrome

Coronary Artery Disease

Volumn 16, Issue 1, 2005, Pages 67-73

  Dell'Omo, Giulia ^a   Penno, Giuseppe ^a   Pucci, Laura ^a   Pellegrini, Giovanni ^b   Scotti, Aurelio ^c   Del Prato, Stefano ^a   Pedrinelli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Italfarmaco SpA   (Italy)

Author keywords

Doxazosin; Endothelial function; Essential; Hypertension; Metabolic syndrome

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IODINE 125; LIPID; MIOVISIN; NITROPRUSSIDE SODIUM; TRIACYLGLYCEROL;

ADULT; ARTICLE; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; DEVICE; DRUG EFFECT; DRUG MECHANISM; FOREARM BLOOD FLOW; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN METABOLISM; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASODILATATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 14044257885     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200502000-00012     Document Type: Article

References (36)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
3. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419
4. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003; 20:255-268.
5. Dell'Omo G, Penno G, Pucci L, Mariani M, Del Prato S, Pedrinelli R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis 2004; 172:403-409.
6. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003; 8:71-86.
7. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996; 9:150S-154S.
8. Alabaster VA, Davey MJ. The α1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. Br J Clin Pharmacol 1986; 21:9s-17s
9. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376
10. Bohme E, Graf H, Schultz G. Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP-formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res 1978; 9:131-143.
11. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62:347-504.
12. Parving HH. Microvascular permeability to plasma proteins in hypertension and diabetes mellitus in man-on the pathogenesis of hypertensive and diabetic micro-angiopathy. Dan Med Bull 1975; 22:217-233.
13. Dell'Omo G, De Negri F, Carmassi F, Ruocco L, Mariani M, Pedrinelli R. Reactive hyperemia and tissue-type plasminogen activator release in hypertensive men. Blood Coagul Fibrinolysis 2003; 14:19-25.
14. Pedrinelli R, Dell'Omo G, Gimelli A, Di Bello V, Talarico L, Corchia A, et al. Myocardial and forearm blood flow reserve in mild-moderate essential hypertensive patients. J Hypertens 1997; 15:667-673.
15. Pedrinelli R, Spessot M, Salvetti A. Reactive hyperaemia during short-term blood flow and pressure changes in the hypertensive forearm. J Hypertens 1990; 8:467-471.
16. Conway J. A vascular abnormality in hypertension; a study of blood flow in the forearm. Circulation 1963; 27:520-529.
17. Sivertsson R. Effect of blood pressure reduction on tissue perfusion. Clin Sci 1956; 15:13-17.
18. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, et al. Microalbuminuria and transvascular albumin leakage in essential hypertension. Hypertension 1999; 34:491-495.
19. Courtney CH, McCance DR, Atkinson AB, Bassett J, Ennis CN, Sheridan B, et al. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003; 52:1147-1152.
20. Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23:307-331.
21. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402.
22. Grimm RH Jr. Alpha 1-antagonists in the treatment of hypertension. Hypertension 1989; 13(suppl): 1131-1136.
23. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:576-580.
24. Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998; 138: 229-235.
25. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in non-diabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14:908-913.
26. Kinoshita M, Shimazu N, Fujita M, Fujimaki Y, Kojima K, Mikuni Y, et al. Doxazosin, an α1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens 2001; 14:267-270.
27. Park JB, Schiffrin EL. Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep 2000; 2:280-288.
28. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16:447-456.
29. Freslon JL, Giudicelli JF Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmac 1983; 80:533-543.
30. Korner PI. Cardiovascular hypertrophy and hypertension: causes and consequences. Blood Press Suppl 1995; 2:6-16.
31. Sivertsson R, Hansson L. Effects of blood pressure reduction on the structural vascular abnormality in skin and muscle vascular beds in human essential hypertension. Clin Sci Mol Med (Suppl) 1976; 3:77s-79s.
32. Parving HH, Kastrup J, Smidt UM. Reduced transcapillary escape of albumin during acute blood pressure-lowering in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1985; 28:797-801.
33. Eggertsen R, Hansson L. Vasodilators in hypertension-a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers. Int J Clin Pharmacol Ther Toxicol 1985; 23:411-423.
34. Hesse B, Parving HH, Lund-Jacobsen H, Noer I. Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment. Circ Res 1976; 39:358-362.
35. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967-1975.
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560-2572.